Author:
Chow Lyndah,Wheat William,Ramirez Dominique,Impastato Renata,Dow Steven
Abstract
AbstractThe canine spontaneous cancer model is increasingly utilized to evaluate new combined cancer immunotherapy approaches. While the major leukocyte subsets and phenotypes are closely related in dogs and humans, the functionality of T cells and antigen presenting cells in the two species has not been previously compared in detail. Such information would be important in interpreting immune response data and evaluating the potential toxicities of new cancer immunotherapies in dogs. To address this question, we used in vitro assays to compare the transcriptomic, cytokine, and proliferative responses of activated canine and human T cells, and also compared responses in activated macrophages. Transcriptomic analysis following T cell activation revealed shared expression of 515 significantly upregulated genes and 360 significantly downregulated immune genes. Pathway analysis identified 33 immune pathways shared between canine and human activated T cells, along with 34 immune pathways that were unique to each species. Activated human T cells exhibited a marked Th1 bias, whereas canine T cells were transcriptionally less active overall. Despite similar proliferative responses to activation, canine T cells produced significantly less IFN-γ than human T cells. Moreover, canine macrophages were significantly more responsive to activation by IFN-γ than human macrophages, as reflected by co-stimulatory molecule expression and TNF-α production. Thus, these studies revealed overall broad similarity in responses to immune activation between dogs and humans, but also uncovered important key quantitative and qualitative differences, particularly with respect to T cell responses, that should be considered in designing and evaluating cancer immunotherapy studies in dogs.
Funder
Shipley Family Foundation
National Cancer Center
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. (2022) NCI-funded Canine Immunotherapy Clinical Trials: A New Comparative Oncology Research Network Builds on the Progress of Its Predecessor. https://dctd.cancer.gov/NewsEvents/20221117_canine.htm.
2. Dow, S. A role for dogs in advancing cancer immunotherapy research. Front. Immunol. 10, 2935. https://doi.org/10.3389/fimmu.2019.02935 (2019).
3. Gardner, H. L., Fenger, J. M. & London, C. A. Dogs as a model for cancer. Annu. Rev. Anim. Biosci. https://doi.org/10.1146/annurev-animal-022114-110911 (2016).
4. Khanna, C. et al. The dog as a cancer model. Nat. Biotechnol. 24, 1065–1066. https://doi.org/10.1038/nbt0906-1065b (2006).
5. Teske, E., Rutteman, G. R., Ingh, T. S., van Noort, R. & Misdorp, W. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): A randomized clinical trial in dogs with mammary carcinoma. Anticancer Res. 18, 1015–9 (1998).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献